GlassScriptPhysician profile
Amber Sanchez
NPI 1700963907
$33,017.08
in general payments reported to CMS, 2019-2025
13 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,605 · 2020: $87.00 · 2022: $7,776 · 2023: $5,779 · 2024: $13K · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,063 · Travel and Lodging: $2,537 · Food and Beverage: $1,137 · Education: $11.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,800.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,062.50 |
| Travel and Lodging | $2,537.47 |
| Food and Beverage | $1,136.51 |
| Education | $11.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $13,008.05 | 2024 | Uvadex |
| Terumo Bct, INC. | $10,168.13 | 2019-2023 | Trima Accel |
| Argenx US, INC. | $7,776.32 | 2022 | |
| Kaneka Medical America LLC | $1,541.73 | 2019-2025 | Apheresis Machine |
| Fresenius Kabi USA, LLC | $230.29 | 2024 | Amicus Separator |
| Kite Pharma, INC. | $57.14 | 2024 | Yescarta |
| Calliditas Therapeutics US INC. | $56.60 | 2024 | |
| Viiv Healthcare Company | $47.61 | 2023-2024 | Cabenuva |
| Aurinia Pharma U.S., INC. | $43.99 | 2023 | Lupkynis |
| Therakos LLC | $35.30 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.97 | 2023 | Enhertu |
| Abbvie INC. | $15.00 | 2024 | |
| Travere Therapeutics, INC. | $11.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.